Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Simulations Plus Software Used in Regulatory Submittals

Published: Wednesday, May 15, 2013
Last Updated: Wednesday, May 15, 2013
Bookmark and Share
US FDA, UK MHRA, and European EMA accept simulation results in applications.

Simulations Plus, Inc. announced that results of simulations using its GastroPlus™ software have been submitted to major regulatory agencies as part of applications by its customers.

John DiBella, vice president of marketing and sales for Simulations Plus, noted, “The first submittal to a regulatory agency was reported by Pfizer in 2008, which resulted in Pfizer being allowed to forego a human trial after GastroPlus simulations showed that it would not be necessary. In the past 12 months, four additional customers have submitted simulation results to the U.S. Food and Drug Administration (FDA), the European Medical Agency (EMA), and the British Medical Health Regulatory Agency (MHRA). Each of these involved a consulting contract with Simulations Plus to assist the sponsor with the GastroPlus simulations and model development. Simulations Plus also provided assistance in preparation of the submittals to the regulatory agencies. The acceptance of simulation results by these agencies is an indication of the growing importance of simulation and modeling technology in pharmaceutical research and development.”

Walt Woltosz, chairman and chief executive officer of Simulations Plus, added: “The four submittals John describes resulted in:
1.    Eliminating a clinical trial to demonstrate that fasted and fed states would not produce significantly different results for the absorption of the drug candidate.
2.    Identifying the particle size specification for a re-engineered product to ensure bioequivalence to an existing product.
3.    Explaining the variations observed in different formulations.
4.    Scaling complex processes involving metabolism and carrier-mediated transport from adult to pediatric/neonate populations.

These four submissions signal a developing trend for the use of simulation and modeling results to reduce the cost and time to bring new drug products to market. Note that these four involved Simulations Plus consulting services. A number of other submittals have been made by sponsors on their own. Regulatory agencies in the U.S., Europe, China, and Japan all have GastroPlus for their internal use, so sponsors can submit GastroPlus input files to these agencies to make evaluation of results fast and convenient. In time, we believe other sponsors will increasingly utilize powerful simulation software to help streamline the regulatory process and provide regulators with accurate data for evaluation purposes.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Simulations Plus Reports First Quarter FY2011 Financial Results
Pharmaceutical software and services revenues up 18%, words+ subsidiary up 8.3%, consolidated earnings up 32%, and EPS up 34% from 1QFY10.
Monday, January 17, 2011
Scientific News
How it Works: Advanced Data Analysis Using Visualization
Visualisation of data can be used to help molecular biologists tackle the vast datasets their experiments create.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Supercomputers Could Improve Cancer Diagnostics
Researchers push the boundaries of cancer research through high-performance computing to map the human immunone.
Systems Medicine – The Future Approach to Diseases
Review give insight into the future of understanding the body and its mechanisms through systems medicine.
Genetic Signature Linked to Cancer Prognosis Identified
The results of the analysis of 8,161 tissue samples could in the future help clinicians decide how best to treat a patient as well as aid the development of new targeted treatments.
Mapping the Human Immune System
Researchers try to harness supercomputers to create the first map of the human immune system.
Microsatellites Linked to Cancer
DNA repeat stretches, called microsatellites, play a greater role in cancer progression and survival that previously thought.
Universal Flu Vaccine Designed by Scientists
An international team of scientists have designed a new generation of universal flu vaccines to protect against future global pandemics that could kill millions.
Faecal Bacteria Linked to Body Fat
Researchers at King’s College London have found a new link between the diversity of bacteria in human poo – known as the human faecal microbiome - and levels of abdominal body fat.
Scroll Up
Scroll Down

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos